Elanco Animal Health (ELAN) said Tuesday that it expects low double-digit adjusted earnings per share growth from 2026 through 2028, as well as revenue growth in the mid-single digit organic constant currency.
Elanco also said it plans to close its German animal research and development facility and will reduce its manufacturing workforce, although the company didn't disclose how many positions will be eliminated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments